Noven Fails Phase III Lithium Study (NOVN)
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that a Phase 3 clinical study of its developmental once-daily lithium carbonate product did not meet its primary endpoint with statistical significance (p-value ≤ ...Read Full Story »

